31
Investor Presentation January 2012

Biocon Investor Presentation_Q3_FY12

  • Upload
    biocon

  • View
    661

  • Download
    0

Embed Size (px)

DESCRIPTION

 

Citation preview

  • 1. Investor PresentationJanuary 2012

2. SAFE HARBORCertain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties andassumptions that could cause actual results to differ materially from those contemplatedin such forward-looking statements. Important factors that could cause actual results todiffer materially from our expectations include, amongst others general economic andbusiness conditions in India, our ability to successfully implement our strategy, ourresearch and development efforts, our growth and expansion plans and technologicalchanges, changes in the value of the Rupee and other currency changes, changes in theIndian and international interest rates, change in laws and regulations that apply to theIndian and global biotechnology and pharmaceuticals industries, increasing competitionin and the conditions of the Indian biotechnology and pharmaceuticals industries,changes in political conditions in India and changes in the foreign exchange controlregulations in India. Neither our company, nor our directors, nor any of their respectiveaffiliates have any obligation to update or otherwise revise any statements reflectingcircumstances arising after this date or to reflect the occurrence of underlying events,even if the underlying assumptions do not come to fruition.2 3. AGENDA BIOCON SNAPSHOT BRANDED FORMULATIONS STRATEGIC ALLIANCES RESEARCH & DEVELOPMENT FINANCIAL HIGHLIGHTS3 4. BIOCON SNAPSHOT 5. INTRODUCTION Biocon is an emerging, global Bio-pharmaceutical enterprise,focused on innovation to develop affordable products and servicesfor patients, partners and healthcare systems across the world. Biocon is committed towards: Reducing therapy costs of chronic diseases. (diabetes, cancer & auto-immune diseases) Strategic Research and marketing partnerships that provide global access Leveraging the India advantage to deliver high value, licensable R&D assets 5 6. BUSINESS STRUCTURE & HOLDINGSBiocon Research , India | 100%R&D- Novel MoleculesBiocon Biopharmaceuticals | 100%Mabs and Biosimilars~61%| PromotersBiocon Sdn. Bhd, Malaysia | 100%PRODUCTS~ 7 % | Employees & ESOP trust Biocon Overseas subsidiary~32 % | PublicBiocon SA, Switzerland | 100%Overseas subsidiaryNeoBiocon, UAE | 50%Overseas subsidiarySyngene International, India | 100%Custom research, drug discovery RESEARCHClinigene International, India | 100% SERVICESClinical development 6 7. A PORTFOLIO BASED APPROACHInsulins & OtherBranded ResearchNovel Statins Immuno BiopharmaFormulationsServices Molecules Suppressants PortfolioConstituents StatinsSimvastatin, Atorvastatin, Lovastatin, Rosuvastatin, Fluvastatin & Pravastatin Insulins & Insulin, Glargine & 2 Analogs (under development) Immuno suppressantsTacrolimus, MMF & MPA Other Biopharma Orlistat, Fidaxomicin, 50+ other molecules Branded Formulations Diabetology, Cardiology, Nephrology, Oncology, Immunotherapy, Comprehensive Care Research ServicesSyngene (Custom Research)Clinigene (Clinical research) Novel MoleculesIN-105, Itolizumab and others7 8. A RISK BALANCED GROWTH STRATEGY SmallMolecules Research Biosimilars Services(Biologics &Growth Insulins)VerticalsNovel Branded MoleculesFormulationsEMERGING MARKETS FOCUSEMERGING MARKETS FOCUS8 9. RESEARCH SERVICES9 10. BRANDED FORMULATIONS 11. BRANDED FORMULATIONS : THERAPEUTICS SEGMENTS 11 12. BRANDED FORMULATIONS : PRODUCTS & MARKETSINDIA PRODUCT RANKINGS*CardiologyMyokinase 2Oncotherapeutics BioMAb EGFR2 Abraxane 3ImmunotherapyTbis2 Picon2 * November MAT 2011 12 13. BIOCONS INSULIN BUSINESS (INDIA)MAT November 2011 YoY Biocons ranking Biocons market share bygrowth for value sales of 40volume:IU insulin: #4 in overall insulin Market: 18%40 IU Insulin: 11% #3 in the 40 IU Insulin market36% Biocon:Glargine vials: 68% #1 in the Glargine vial marketNovo Nordisk: 18%Source: IMS Health MAT, November 2011 10 players inBiocon has the insulinboth OADsspaceand insulins60 of these are in the oralanti-diabetics space 63 players operate in the anti-diabetics market 13 14. BRANDED FORMULATIONS : INSUPen ease LAUNCHDesigned for accuracy, efficiency, safety & economy. Launched in October, 2011 Based on proprietary German technology Reusable delivery device capable of delivering both InsugenTM & BasalogTM One Call Does All Support helpline Expected to add further impetus to branded formulations sales in H2FY1214 15. STRATEGIC ALLIANCES 16. STRATEGIC PARTNERSHIPS 16 17. BIOSIMILARS COMMERCIALIZATION PARTNERSHIP: PFIZER Insulin and Insulin analogs Combines Biocons research and manufacturing capabilities with Pfizers global marketing prowessGlobal agreement for commercialization of Biocons biosimilar versions ofInsulin & Insulin Analogs: rh- Insulin, Glargine, Aspart, and Lispro.Pfizer will have exclusive rights (with some exceptions) to commercialize these products globally. Biocon will be responsible for clinical development, manufacture, supply, &regulatory approvals.Upfront from Pfizer 100 USD mn+ New manufacturing facility setup milestone payments 100 USD mn (in escrow a/c)+ Development, regulatory & launch milestone payments 150 USD mn+ Payments linked to supplies and sales. 17 18. Diabetes Prevalence (% of population)Diabetics (absolute nos. )Source: International Diabetes Atlas 201118 19. BIOSIMILARS: GLOBAL OPPORTUNITY Total 2010 Insulin Market USD ~15 Bn Total 2010 Biologics Market* USD ~138 Bn rh insulinBiocon s21% TargetOpportunityLispro 14%Glargine32% detemir8% Aspart glulisine 2%23% Expected to be USD ~20 Bn in 2020 Expected to be USD ~200 Bn in 2015* Biologics Includes MAbs, Vaccines, Growth Factors Source: Industry reports, IMS data 19 20. BIOSIMILARS COMMERCIALIZATION PARTNERSHIP: MYLANMonoclonal Antibodies (MAbs)Combines Biocons R&D and manufacturing prowess ofnovel biologics/ bio-generics with Mylans regulatory & commercialization capabilities in the US and EuropeMarket size for product portfolio in 2010 : USD ~30 bnExclusive collaboration for development and commercialization of.complex biogenerics and biosimilars. A basket of products with patents expiring between 2014-18. MAbs in particular.Mylan and Biocon to share development and capital costs. Mylan will have exclusive commercialization rights in the regulated markets; profits to be shared Biocon and Mylan to have co-exclusive commercialization rights in other markets.20 21. Research & Development 22. RESEARCH PARTNERSHIPS : HIGH POTENTIAL PRODUCT PIPELINE US IND filed by partner (Amylin) for AC165198 Several Bi-specific fusion proteins under development with IATRICa * Including molecules from collaborative programs22 23. ANTI-CD6 MAb: ItolizumabDrug Highlights Targets CD6CD6 is a type 1 cell membrane glycoprotein belonging to the scavenger receptor cysteine-rich(SRCR) super family group B.CD6 is predominantly expressed by T cells & a B cell subset.CD6 binds ALCAM (activated leukocyte cell adhesion molecule)which is expressed on: Activated T, cells, B cells & monocytes.Skin fibroblasts, keratinocytes, rheumatoid arthritis synovium.Drug Development : Database lock for Phase II(b) clinical trial in Psoriasis done. Data Analysis ongoing TREAT-PLAQ Study in Psoriasis Total Patient Enrollment 223Trial Duration52 WeeksInterim Data Presented28 Weeks 23 24. TREAT PLAQ STUDY: SUMMARY OF RESULTS#PRIMARY ENDPOINT Result*Statistically significant patient cohort with PASI 75 at 12 Weeks SECONDARY ENDPOINTSSignificant Proportion of subjects achieving PASI 50 and PASI 90Safety & Tolerability Improvement in PGA scores Considerable Proportion of subjects with PGA score of clear or minimal PASI: Psoriasis Area Severity Index PGA: Physicians Global Assessment *p